Click here for slides on this topic


Clopidogrel

An oral antiplatelet agent of the thienopyridine class used to inhibit blood clots in coronary artery disease (CAD), peripheral vascular disease (PVD), and cerebrovascular disease.
The following content matched the glossary term: Clopidogrel

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

Clinical Insights April 2013

Top

The latest diabetes literature exploring diabetes guidelines, diabetes treatment, diabetes management, and diabetes prevention with commentary from diabetes experts.

Effect of platelet inhibition with cangrelor during PCI on ischemic events

Top

Bhatt DL, Stone GW, Mahaffey KW, et al for the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303-1313. Percutaneous coronary intervention (PCI) with stent implantation is frequently used to reduce ischemic complications among patients with acute coronary syndrome (ACS). Despite advances in adjunctive pharmacologic therapy, thrombotic complications during PCI remain a concern.

Measures for Reducing the Incidence of Events in Patients With CVD Are Available but Too Often Are Not Applied(2)

Top

Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update. A Statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2001;38:1581-1583. In 1995, the American Heart Association published, and the American College of Cardiology endorsed, the original consensus statement on the secondary prevention of heart attack and death in patients with established atherosclerotic cardiovascular disease (CVD).



Slide Library Results

Search Results for: Clopidogrel Slides Found: 10
CHAMPION PHOENIX: Randomization
CHAMPION PHOENIX: Baseline Characteristics
CHAMPION PHOENIX: Rate of the Primary Efficacy Endpoint
CHAMPION PHOENIX: Rate of the Primary Efficacy Endpoint at 30 Days
CHAMPION PHOENIX: Rate of the Key Secondary Efficacy Endpoint
CHAMPION PHOENIX: Rate of the Primary Safety Endpoint
CHAMPION PHOENIX: Rate of Intraprocedural Stent Thrombosis
CHAMPION PHOENIX: Rate of Adverse Events
IDF Type 2 Diabetes Guidelines CVD Risk Reduction Treatment | NDEI
Antiplatelet Therapy Recommendations ADA Guidelines | NDEI PPT